(PFE, TWC, LDR, CLP, CRWE) Stocks in Focus by DrStockPick.com

Posted on 12/31/2011 @ 2:01 PM in #Finance by DrStockPick 0 comments

Pfizer, Inc. (NYSE:PFE) At PFE, they apply science and their global resources to improve health and well-being at every stage of life. They strive to set the standard for quality, safety and value in the discovery, development and manufacturing of medicines for people and animals. Their diversified global health care portfolio includes human and animal biologic and small molecule medicines and vaccines, as well as nutritional products and many of the world's best-known consumer products. Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. Consistent with their responsibility as the world's leading biopharmaceutical company, they also collaborate with health care providers, governments and local communities to support and expand access to reliable, affordable health care around the world. For more than 150 years, Pfizer has worked to make a difference for all who rely on them. Read

(PFE, CRWE, BSI, AG, UNP) Featured Stocks by PennyOTCStock.com

Posted on 12/31/2011 @ 2:01 PM in #Finance by pennyotc 0 comments

Consistent with our responsibility as the world's leading biopharmaceutical company, Pfizer Inc. (NYSE:PFE) collaborates with health care providers, governments and local communities to support and expand access to reliable, affordable health care around the world. For more than 150 years, Pfizer has worked to make a difference for all who rely on us. Pfizer announced yesterday that the U.S. Food and Drug Administration (FDA) has granted approval of the Company's pneumococcal conjugate vaccine Prevnar 13®* (Pneumococcal 13-valent Conjugate Vaccine [Diphtheria CRM197 Protein]) as a single dose for use in adults. Prevnar 13 is indicated for adults 50 years of age and older for active immunization for the prevention of pneumonia and invasive disease caused by the 13 Streptococcus pneumoniae (S. pneumoniae) serotypes contained in the vaccine. Pneumococcal disease (PD) is a leading public health issue in adults 50 years of age and older, a population rapidly increasing in the United States. In this population,

(PFE, CRWE, LINTA, TESS, FRAN) Noticeable Stock by CRWEPicks.Com

Posted on 12/31/2011 @ 2:01 PM in #Finance by Blayne 0 comments

Pfizer Inc. (NYSE:PFE) announced yesterday that the U.S. Food and Drug Administration (FDA) has granted approval of the Company's pneumococcal conjugate vaccine Prevnar 13®* (Pneumococcal 13-valent Conjugate Vaccine [Diphtheria CRM197 Protein]) as a single dose for use in adults. Prevnar 13 is indicated for adults 50 years of age and older for active immunization for the prevention of pneumonia and invasive disease caused by the 13 Streptococcus pneumoniae (S. pneumoniae) serotypes contained in the vaccine. Read full article at: http://crwepicks.com/19410/top-news/pfe-crwe-linta-tess-fran-noticeable-stock-by-crwepickscom/ THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY! ***************************** Disclaimer: Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment.The CRWEPicks.com publisher and its affiliates and contractors are not registered investment advisers or broker/dealers. Our disclaimer (http://crwepicks.com/disclaimer )

(PFE, CRWE, OMI, TYL, IBM) Noticeable Stocks by PennyToBuck.com

Posted on 12/31/2011 @ 2:01 PM in #Finance by Terry1 0 comments

The diversified global health care portfolio at Pfizer Inc. (NYSE:PFE) includes human and animal biologic and small molecule medicines and vaccines, as well as nutritional products and many of the world's best-known consumer products. At Pfizer, we apply science and our global resources to improve health and well-being at every stage of life. We strive to set the standard for quality, safety and value in the discovery, development and manufacturing of medicines for people and animals. Pfizer announced yesterday that the U.S. Food and Drug Administration (FDA) has granted approval of the Company's pneumococcal conjugate vaccine Prevnar 13®* (Pneumococcal 13-valent Conjugate Vaccine [Diphtheria CRM197 Protein]) as a single dose for use in adults. Prevnar 13 is indicated for adults 50 years of age and older for active immunization for the prevention of pneumonia and invasive disease caused by the 13 Streptococcus pneumoniae (S. pneumoniae) serotypes contained in the vaccine. Pneumococcal disease (PD) is a

(PFE, CRWE, RUE, AIRM, EXPE) Stock Highlights by DoubleInStocks.com

Posted on 12/31/2011 @ 2:01 PM in #Finance by fairycool 0 comments

“Pneumococcal disease, including pneumonia, in adults 50 years and older represents a significant personal and societal health burden in the United States. The FDA approval of Prevnar 13 for these adults offers the potential to contribute to the health of millions of aging Americans,” said Ian Read, chairman and chief executive officer, Pfizer Inc. (NYSE:PFE) “This approval is representative of Pfizer's dedication to discovering and bringing to market life-changing medicines and vaccines.” Pfizer announced yesterday that the U.S. Food and Drug Administration (FDA) has granted approval of the Company's pneumococcal conjugate vaccine Prevnar 13®* (Pneumococcal 13-valent Conjugate Vaccine [Diphtheria CRM197 Protein]) as a single dose for use in adults. Prevnar 13 is indicated for adults 50 years of age and older for active immunization for the prevention of pneumonia and invasive disease caused by the 13 Streptococcus pneumoniae (S. pneumoniae) serotypes contained in the vaccine. Pneumococcal disease (PD)

(PFE, CRWE, ADGE, CUR, LSG) Notable Stocks by CRWEFinance.com

Posted on 12/31/2011 @ 2:01 PM in #Finance by financecrwe 0 comments

At Pfizer Inc. (NYSE:PFE), we apply science and our global resources to improve health and well-being at every stage of life. We strive to set the standard for quality, safety and value in the discovery, development and manufacturing of medicines for people and animals. The diversified global health care portfolio at Pfizer includes human and animal biologic and small molecule medicines and vaccines, as well as nutritional products and many of the world's best-known consumer products. Pfizer announced yesterday that the U.S. Food and Drug Administration (FDA) has granted approval of the Company's pneumococcal conjugate vaccine Prevnar 13®* (Pneumococcal 13-valent Conjugate Vaccine [Diphtheria CRM197 Protein]) as a single dose for use in adults. Prevnar 13 is indicated for adults 50 years of age and older for active immunization for the prevention of pneumonia and invasive disease caused by the 13 Streptococcus pneumoniae (S. pneumoniae) serotypes contained in the vaccine. “Pneumococcal disease, including

(PFE, CRWE, SJW, DRC, MDC) Stocks under Consideration by BestOtc.com

Posted on 12/31/2011 @ 2:01 PM in #Finance by bestotcstocks 0 comments

Pfizer, Inc. (NYSE:PFE) PFE previously announced that the U.S. Food and Drug Administration (FDA) has granted approval of the Company's pneumococcal conjugate vaccine Prevnar 13®* (Pneumococcal 13-valent Conjugate Vaccine [Diphtheria CRM197 Protein]) as a single dose for use in adults. Prevnar 13 is indicated for adults 50 years of age and older for active immunization for the prevention of pneumonia and invasive disease caused by the 13 Streptococcus pneumoniae (S. pneumoniae) serotypes contained in the vaccine. Read full article at: http://bestotc.com/19490/stock-alerts/pfe-crwe-sjw-drc-mdc-stocks-under-consideration-by-bestotccom/ THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY! ************************** Disclaimer: Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. BestOtc.com publisher and its affiliates and contractors are not registered investment advisers or broker/dealers.Our disclaimer ( http://bestotc.com/disclaimer) is to

(PFE, CRWE, SVM, TEA, DGI) Featured Stocks by PennyGovernance.com

Posted on 12/31/2011 @ 2:00 PM in #Finance by Marcia 0 comments

Pfizer, Inc. (NYSE:PFE) Prevnar 13 uses Company-pioneered conjugate technology that links pneumococcal polysaccharide sugar chains found on the surface of each bacterial serotype with a carrier protein. Prevnar 13 uses the carrier protein CRM197, which has more than 20 years of clinical and commercial use in vaccines. PFE previously reported that the U.S. Food and Drug Administration (FDA) has granted approval of the Company's pneumococcal conjugate vaccine Prevnar 13®* (Pneumococcal 13-valent Conjugate Vaccine [Diphtheria CRM197 Protein]) as a single dose for use in adults. Prevnar 13 is indicated for adults 50 years of age and older for active immunization for the prevention of pneumonia and invasive disease caused by the 13 Streptococcus pneumoniae (S. pneumoniae) serotypes contained in the vaccine. At PFE, they apply science and their global resources to improve health and well-being at every stage of life. They strive to set the standard for quality, safety and value in the discovery, development and

(PFE, TWC, LDR, CLP, CRWE) Stocks in Focus by DrStockPick.com

Posted on 12/31/2011 @ 1:04 PM in #Finance by DrStockPick 1 comments

Pfizer, Inc. (NYSE:PFE) At PFE, they apply science and their global resources to improve health and well-being at every stage of life. They strive to set the standard for quality, safety and value in the discovery, development and manufacturing of medicines for people and animals. Their diversified global health care portfolio includes human and animal biologic and small molecule medicines and vaccines, as well as nutritional products and many of the world's best-known consumer products. Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. Consistent with their responsibility as the world's leading biopharmaceutical company, they also collaborate with health care providers, governments and local communities to support and expand access to reliable, affordable health care around the world. For more than 150 years, Pfizer has worked to make a difference for all who rely on them. Read

(PFE, CRWE, BSI, AG, UNP) Featured Stocks by PennyOTCStock.com

Posted on 12/31/2011 @ 1:03 PM in #Finance by pennyotc 0 comments

Consistent with our responsibility as the world's leading biopharmaceutical company, Pfizer Inc. (NYSE:PFE) collaborates with health care providers, governments and local communities to support and expand access to reliable, affordable health care around the world. For more than 150 years, Pfizer has worked to make a difference for all who rely on us. Pfizer announced yesterday that the U.S. Food and Drug Administration (FDA) has granted approval of the Company's pneumococcal conjugate vaccine Prevnar 13®* (Pneumococcal 13-valent Conjugate Vaccine [Diphtheria CRM197 Protein]) as a single dose for use in adults. Prevnar 13 is indicated for adults 50 years of age and older for active immunization for the prevention of pneumonia and invasive disease caused by the 13 Streptococcus pneumoniae (S. pneumoniae) serotypes contained in the vaccine. Pneumococcal disease (PD) is a leading public health issue in adults 50 years of age and older, a population rapidly increasing in the United States. In this population,

(PFE, CRWE, LINTA, TESS, FRAN) Noticeable Stock by CRWEPicks.Com

Posted on 12/31/2011 @ 1:03 PM in #Finance by Blayne 0 comments

Pfizer Inc. (NYSE:PFE) announced yesterday that the U.S. Food and Drug Administration (FDA) has granted approval of the Company's pneumococcal conjugate vaccine Prevnar 13®* (Pneumococcal 13-valent Conjugate Vaccine [Diphtheria CRM197 Protein]) as a single dose for use in adults. Prevnar 13 is indicated for adults 50 years of age and older for active immunization for the prevention of pneumonia and invasive disease caused by the 13 Streptococcus pneumoniae (S. pneumoniae) serotypes contained in the vaccine. Read full article at: http://crwepicks.com/19410/top-news/pfe-crwe-linta-tess-fran-noticeable-stock-by-crwepickscom/ THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY! ***************************** Disclaimer: Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment.The CRWEPicks.com publisher and its affiliates and contractors are not registered investment advisers or broker/dealers. Our disclaimer (http://crwepicks.com/disclaimer )

(PFE, CRWE, RUE, AIRM, EXPE) Stock Highlights by DoubleInStocks.com

Posted on 12/31/2011 @ 1:02 PM in #Finance by fairycool 0 comments

“Pneumococcal disease, including pneumonia, in adults 50 years and older represents a significant personal and societal health burden in the United States. The FDA approval of Prevnar 13 for these adults offers the potential to contribute to the health of millions of aging Americans,” said Ian Read, chairman and chief executive officer, Pfizer Inc. (NYSE:PFE) “This approval is representative of Pfizer's dedication to discovering and bringing to market life-changing medicines and vaccines.” Pfizer announced yesterday that the U.S. Food and Drug Administration (FDA) has granted approval of the Company's pneumococcal conjugate vaccine Prevnar 13®* (Pneumococcal 13-valent Conjugate Vaccine [Diphtheria CRM197 Protein]) as a single dose for use in adults. Prevnar 13 is indicated for adults 50 years of age and older for active immunization for the prevention of pneumonia and invasive disease caused by the 13 Streptococcus pneumoniae (S. pneumoniae) serotypes contained in the vaccine. Pneumococcal disease (PD)

(PFE, CRWE, OMI, TYL, IBM) Noticeable Stocks by PennyToBuck.com

Posted on 12/31/2011 @ 1:02 PM in #Finance by Terry1 0 comments

The diversified global health care portfolio at Pfizer Inc. (NYSE:PFE) includes human and animal biologic and small molecule medicines and vaccines, as well as nutritional products and many of the world's best-known consumer products. At Pfizer, we apply science and our global resources to improve health and well-being at every stage of life. We strive to set the standard for quality, safety and value in the discovery, development and manufacturing of medicines for people and animals. Pfizer announced yesterday that the U.S. Food and Drug Administration (FDA) has granted approval of the Company's pneumococcal conjugate vaccine Prevnar 13®* (Pneumococcal 13-valent Conjugate Vaccine [Diphtheria CRM197 Protein]) as a single dose for use in adults. Prevnar 13 is indicated for adults 50 years of age and older for active immunization for the prevention of pneumonia and invasive disease caused by the 13 Streptococcus pneumoniae (S. pneumoniae) serotypes contained in the vaccine. Pneumococcal disease (PD) is a

(PFE, CRWE, ADGE, CUR, LSG) Notable Stocks by CRWEFinance.com

Posted on 12/31/2011 @ 1:02 PM in #Finance by financecrwe 0 comments

At Pfizer Inc. (NYSE:PFE), we apply science and our global resources to improve health and well-being at every stage of life. We strive to set the standard for quality, safety and value in the discovery, development and manufacturing of medicines for people and animals. The diversified global health care portfolio at Pfizer includes human and animal biologic and small molecule medicines and vaccines, as well as nutritional products and many of the world's best-known consumer products. Pfizer announced yesterday that the U.S. Food and Drug Administration (FDA) has granted approval of the Company's pneumococcal conjugate vaccine Prevnar 13®* (Pneumococcal 13-valent Conjugate Vaccine [Diphtheria CRM197 Protein]) as a single dose for use in adults. Prevnar 13 is indicated for adults 50 years of age and older for active immunization for the prevention of pneumonia and invasive disease caused by the 13 Streptococcus pneumoniae (S. pneumoniae) serotypes contained in the vaccine. “Pneumococcal disease, including

(PFE, CRWE, SJW, DRC, MDC) Stocks under Consideration by BestOtc.com

Posted on 12/31/2011 @ 1:02 PM in #Finance by bestotcstocks 0 comments

Pfizer, Inc. (NYSE:PFE) PFE previously announced that the U.S. Food and Drug Administration (FDA) has granted approval of the Company's pneumococcal conjugate vaccine Prevnar 13®* (Pneumococcal 13-valent Conjugate Vaccine [Diphtheria CRM197 Protein]) as a single dose for use in adults. Prevnar 13 is indicated for adults 50 years of age and older for active immunization for the prevention of pneumonia and invasive disease caused by the 13 Streptococcus pneumoniae (S. pneumoniae) serotypes contained in the vaccine. Read full article at: http://bestotc.com/19490/stock-alerts/pfe-crwe-sjw-drc-mdc-stocks-under-consideration-by-bestotccom/ THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY! ************************** Disclaimer: Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. BestOtc.com publisher and its affiliates and contractors are not registered investment advisers or broker/dealers.Our disclaimer ( http://bestotc.com/disclaimer) is to

(PFE, CRWE, SVM, TEA, DGI) Featured Stocks by PennyGovernance.com

Posted on 12/31/2011 @ 1:01 PM in #Finance by Marcia 0 comments

Pfizer, Inc. (NYSE:PFE) Prevnar 13 uses Company-pioneered conjugate technology that links pneumococcal polysaccharide sugar chains found on the surface of each bacterial serotype with a carrier protein. Prevnar 13 uses the carrier protein CRM197, which has more than 20 years of clinical and commercial use in vaccines. PFE previously reported that the U.S. Food and Drug Administration (FDA) has granted approval of the Company's pneumococcal conjugate vaccine Prevnar 13®* (Pneumococcal 13-valent Conjugate Vaccine [Diphtheria CRM197 Protein]) as a single dose for use in adults. Prevnar 13 is indicated for adults 50 years of age and older for active immunization for the prevention of pneumonia and invasive disease caused by the 13 Streptococcus pneumoniae (S. pneumoniae) serotypes contained in the vaccine. At PFE, they apply science and their global resources to improve health and well-being at every stage of life. They strive to set the standard for quality, safety and value in the discovery, development and

(CRWE, SONC, ELRC, LBTYA) Stock Updates by CRWESelect.com

Posted on 12/31/2011 @ 1:01 PM in #Finance by CRWESelect 0 comments

Crown Equity Holdings Inc. (CRWE) Video marketing has been presumed as a difficult way to market the products but it's a misconception because now you can easily turn your living room or bedroom a market place through a short video. Even with a simple camera, digital camera or web cam, you can shoot a short descriptive video about your product or website and put it to video stream over internet. The more your video is being watched, the more traffic is generated to your blog or website. Crown Equity Holdings Inc., together with its digital network, currently provides electronic media services specializing in online publishing, which brings together targeted audiences and advertisers. Read full article at: http://crweselect.com/27999/stock-alerts/crwe-sonc-elrc-lbtya-stock-updates-by-crweselectcom/ THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY! ******************* Disclaimer: Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment.

(PFE, CRWE, INXI, MYGN, VMED) Stock under Consideration by PennyOmega.com

Posted on 12/31/2011 @ 1:01 PM in #Finance by Bokharian 0 comments

Pfizer, Inc. (NYSE:PFE) PFE recently announced that the U.S. Food and Drug Administration (FDA) has granted approval of the Company's pneumococcal conjugate vaccine Prevnar 13®* (Pneumococcal 13-valent Conjugate Vaccine [Diphtheria CRM197 Protein]) as a single dose for use in adults. Prevnar 13 is indicated for adults 50 years of age and older for active immunization for the prevention of pneumonia and invasive disease caused by the 13 Streptococcus pneumoniae (S. pneumoniae) serotypes contained in the vaccine. Read full article at: http://pennyomega.com/19171/stock-alerts/crwe-inxi-mygn-vmed-stock-under-consideration-by-pennyomegacom/ THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY! ******************************** Disclaimer: Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. PennyOmega.com publisher and its affiliates and contractors are not registered investment advisers or broker/dealers. Our disclaimer is to be read and fully

PFE, DIS, WCN, WBS - CRWESelect.com Stock News! Pfizer, The Walt Disney Company, Waste Connections, Webster Financial Corporation (Video Included Inside)

Posted on 12/31/2011 @ 1:01 PM in #Finance by CRWESelect 0 comments

Pfizer, Inc. (NYSE:PFE) PFE announced that the U.S. Food and Drug Administration (FDA) has granted approval of the Company's pneumococcal conjugate vaccine Prevnar 13®* (Pneumococcal 13-valent Conjugate Vaccine [Diphtheria CRM197 Protein]) as a single dose for use in adults. Prevnar 13 is indicated for adults 50 years of age and older for active immunization for the prevention of pneumonia and invasive disease caused by the 13 Streptococcus pneumoniae (S. pneumoniae) serotypes contained in the vaccine. Prevnar 13 uses Company-pioneered conjugate technology that links pneumococcal polysaccharide sugar chains found on the surface of each bacterial serotype with a carrier protein. Prevnar 13 uses the carrier protein CRM197, which has more than 20 years of clinical and commercial use in vaccines. Pneumococcal disease is a group of infections caused by the bacterium Streptococcus pneumoniae, also known as pneumococcus. The most common manifestation of PD in adults 50 years of age and older is non-bacteremic

(PFE, CRWE, WSM, PKO, ANH) Featured Stock by Stock-PR.com

Posted on 12/31/2011 @ 1:01 PM in #Finance by Jensen1 0 comments

Stock-PR Reporting FREE Daily Stock Alerts From Stock-PR.com Pfizer, Inc. (NYSE:PFE) PFE recently reported that the U.S. Food and Drug Administration (FDA) has granted approval of the Company's pneumococcal conjugate vaccine Prevnar 13®* (Pneumococcal 13-valent Conjugate Vaccine [Diphtheria CRM197 Protein]) as a single dose for use in adults. Prevnar 13 is indicated for adults 50 years of age and older for active immunization for the prevention of pneumonia and invasive disease caused by the 13 Streptococcus pneumoniae (S. pneumoniae) serotypes contained in the vaccine. Prevnar 13 uses Company-pioneered conjugate technology that links pneumococcal polysaccharide sugar chains found on the surface of each bacterial serotype with a carrier protein. Prevnar 13 uses the carrier protein CRM197, which has more than 20 years of clinical and commercial use in vaccines. At PFE, they apply science and their global resources to improve health and well-being at every stage of life. They strive